Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in previously treated advanced NSCLC
NCT02486354Phase 3Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Mar 2010; status: completed.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02486354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486354.